SEC Info - Bristol Myers Squibb Co. - ‘8-K’ for 1/11/21

SEC Info℠

Home

Help

Please Sign In

Bristol Myers Squibb Co. – ‘8-K’ for 1/11/21

On: Monday, 1/11/21, at 7:16am ET · For: 1/11/21 · Accession #: 1140361-21-737 · File #: 1-01136

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/11/21  Bristol Myers Squibb Co.          8-K:7,9     1/11/21   12:4.1M                                   Edgarfilings Ltd.

Current Report — Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     33K 
 2: EX-99.1     Investor Presentation of Bristol-Myers Squibb       HTML     38K 
                Company                                                          
 8: R1          Document and Entity Information                     HTML     60K 
10: XML         IDEA XML File -- Filing Summary                      XML     12K 
 7: XML         XBRL Instance -- brhc10018812_8k_htm                 XML     28K 
 9: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 4: EX-101.DEF  XBRL Definitions -- bmy-20210111_def                 XML     54K 
 5: EX-101.LAB  XBRL Labels -- bmy-20210111_lab                      XML     81K 
 6: EX-101.PRE  XBRL Presentations -- bmy-20210111_pre               XML     58K 
 3: EX-101.SCH  XBRL Schema -- bmy-20210111                          XSD     18K 
11: JSON        XBRL Instance as JSON Data -- MetaLinks               16±    23K 
12: ZIP         XBRL Zipped Folder -- 0001140361-21-000737-xbrl      Zip     22K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C:

i false i NY i 000001427200000142722021-01-112021-01-110000014272us-gaap:CommonStockMember2021-01-112021-01-110000014272bmy:One000NotesDue2025Member2021-01-112021-01-110000014272bmy:CelgeneContingentValueRightsMember2021-01-112021-01-110000014272bmy:BristolMyersSquibbContingentValueRightsMember2021-01-112021-01-110000014272bmy:One750NotesDue2035Member2021-01-112021-01-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): i January 11, 2021

i BRISTOL-MYERS SQUIBB COMPANY

(Exact Name of Registrant as Specified in its Charter)

i Delaware	i 001-01136	i 22-0790350
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)

i 430 East 29th Street, i 14th Floor

i New York, NY i 10016

(Address of Principal Executive Office)

Registrant’s telephone number, including area code: ( i 212) i 546-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

i ☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
i Common Stock, $0.10 Par Value	i BMY	i New York Stock Exchange
i 1.000% Notes due 2025	i BMY25	i New York Stock Exchange
i 1.750% Notes due 2035	i BMY35	i New York Stock Exchange
i Bristol-Myers Squibb Contingent Value Rights	i BMY RT	i New York Stock Exchange
i Celgene Contingent Value Rights	i CELG RT	i New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01.

Regulation FD Disclosure.

On January 11, 2021, Bristol-Myers Squibb Company (the “Company”) posted an investor presentation to its website at: www.bms.com/investors/events-and-presentations.html. A copy of the investor presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information set forth in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise be subject to the liabilities thereof, nor shall it be incorporated by reference into any filing by the Company under the Exchange Act or under the Securities Act of 1933, as amended, whether made before or after the date hereof regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

Item 9.01.

Financial Statements and Exhibits.

(d)

Exhibits

The following exhibit is included as part of this Current Report on Form 8-K:

Exhibit No.		Description
99.1		Investor presentation of Bristol-Myers Squibb Company dated January 11, 2021.
104		The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

EXHIBIT INDEX

Exhibit No.		Description
99.1		Investor presentation of Bristol-Myers Squibb Company dated January 11, 2021.
104		The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BRISTOL-MYERS SQUIBB COMPANY

Dated: January 11, 2021	By:	/s/*Katherine R. Kelly*
	Name:	Katherine R. Kelly
	Title:	Corporate Secretary

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on / For Period end:	1/11/21	None on these Dates
		List all Filings

2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/04/21  Bristol-Myers Squibb Co.          S-8         5/04/21    3:81K                                    Broadridge Fin’l So… Inc
 5/04/21  Bristol-Myers Squibb Co.          S-8 POS     5/04/21    3:85K                                    Broadridge Fin’l So… Inc

↑Top

Filing Submission 0001140361-21-000737 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)